A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

594

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG: Ceralasertib
DRUG: Durvalumab
DRUG: Docetaxel

Sponsor

AstraZeneca

Collaborators

[object Object]